Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA) from its SEC filings: 2025 revenue $677.6 million (+60% vs the year before), net margin 9%, free cash flow $136.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $677.6 million |
| Revenue growth | +60% |
| Net income | $59.0 million |
| Net margin | 8.7% |
| Free cash flow | $136.4 million |
| Diluted EPS | $0.75 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | +56% |
| Cash | $190.0 million |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.